Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Popik

FRI0251 SIRUKUMAB, an ANTI-IL-6 Cytokine Monoclonal Antibody, Leads to Improvements in Work Productivity and General Health Status in Patients With Active Rheumatoid Arthritis Refractory to ANTI-TNF Therapy: Results From the Phase 3 SIRROUND-T Study

2017

English

Related publications

Pms62 Association of Satisfaction With Subcutaneous Anti-TNF Therapy and Clinical Outcomes, Health Status, and Lost Work Productivity in Patients With Rheumatoid Arthritis

English

SAT0182 Sirukumab Leads to Significant and Clinically Meaningful Improvements in Health-Related Quality of Life That Meet or Exceed Normative Values in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post Hoc Analyses of a Phase 3 Trial

2017

English

Genetic Variant in IL-32 Is Associated With the Ex Vivo Cytokine Production of Anti-TNF Treated PBMCs From Rheumatoid Arthritis Patients

Scientific Reports

Multidisciplinary

2018

English

Autoantibody Formation in Patients With Rheumatoid Arthritis Treated With Anti-TNF

Annals of the Rheumatic Diseases

English

The Effects of CD20 Inhibitors Therapy in Comparison to TNF Α Inhibitors Therapy on IL-17 in Patients With Active Rheumatoid Arthritis .

IOSR Journal of Applied Chemistry

2013

English

Infections in Patients With Rheumatoid Arthritis Receiving Anti-Cytokine Therapy: Biological Mechanisms and Clinical Aspects

Reumatismo

Rheumatology

2011

English

Correction: Polymorphisms at Phase I-Metabolizing Enzyme and Hormone Receptor Loci Influence the Response to Anti-TNF Therapy in Rheumatoid Arthritis Patients

Pharmacogenomics Journal

English

Increasing Levels of Circulating Th17 Cells and Interleukin-17 in Rheumatoid Arthritis Patients With an Inadequate Response to Anti-TNF-Α Therapy

Arthritis Research and Therapy

English

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Popik

FRI0251 SIRUKUMAB, an ANTI-IL-6 Cytokine Monoclonal Antibody, Leads to Improvements in Work Productivity and General Health Status in Patients With Active Rheumatoid Arthritis Refractory to ANTI-TNF Therapy: Results From the Phase 3 SIRROUND-T Study

Related publications

Pms62 Association of Satisfaction With Subcutaneous Anti-TNF Therapy and Clinical Outcomes, Health Status, and Lost Work Productivity in Patients With Rheumatoid Arthritis

SAT0182 Sirukumab Leads to Significant and Clinically Meaningful Improvements in Health-Related Quality of Life That Meet or Exceed Normative Values in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post Hoc Analyses of a Phase 3 Trial

Genetic Variant in IL-32 Is Associated With the Ex Vivo Cytokine Production of Anti-TNF Treated PBMCs From Rheumatoid Arthritis Patients

Autoantibody Formation in Patients With Rheumatoid Arthritis Treated With Anti-TNF

The Effects of CD20 Inhibitors Therapy in Comparison to TNF Α Inhibitors Therapy on IL-17 in Patients With Active Rheumatoid Arthritis .

Infections in Patients With Rheumatoid Arthritis Receiving Anti-Cytokine Therapy: Biological Mechanisms and Clinical Aspects

Correction: Polymorphisms at Phase I-Metabolizing Enzyme and Hormone Receptor Loci Influence the Response to Anti-TNF Therapy in Rheumatoid Arthritis Patients

Increasing Levels of Circulating Th17 Cells and Interleukin-17 in Rheumatoid Arthritis Patients With an Inadequate Response to Anti-TNF-Α Therapy

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study